- ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
- LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009)
- LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -20.03 placebo-adjusted delta (p
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
First Tracks Biotherapeutics, Inc. on 6ix
In the deck
Story so far
Earlier from First Tracks Biotherapeutics
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- First Tracks Biotherapeutics Announces Participation in September Investor Conferences
- First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
- First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
- First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Follow First Tracks Biotherapeutics into a list and get an email when it puts out news.
Follow First Tracks Biotherapeutics